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Pneumocystis jirovecii is an unculturable fungus and the causative agent of
Pneumocystis pneumonia, a life-threatening opportunistic infection. Although molecular
diagnosis is often based on the detection of mtLSU rRNA mitochondrial gene, the
number of copies of mitochondrial genes had not been investigated. We developed
and optimized six real-time PCR assays in order to determine the copy number of four
mitochondrial genes (mtSSU rRNA, mtLSU rRNA, NAD1, and CYTB) in comparison to
nuclear genome (DHPS and HSP70) and tested 84 bronchoalveolar fluids of patients
at different stages of the infection. Unexpectedly, we found that copy number of
mitochondrial genes varied from gene to gene with mtSSU rRNA gene being more
represented (37 copies) than NAD1 (23 copies), mtLSU rRNA (15 copies) and CYTB
(6 copies) genes compared to nuclear genome. Hierarchical clustering analysis (HCA)
allowed us to define five major clusters, significantly associated with fungal load
(p = 0.029), in which copy number of mitochondrial genes was significantly different
among them. More importantly, copy number of mtLSU rRNA, NAD1, and CYTB but
not mtSSU rRNA differed according to P. jirovecii physiological state with a decreased
number of copies when the fungal load is low. This suggests the existence of a mixture
of various subspecies of mtDNA that can harbor different amplification rates. Overall, we
revealed here an unexpected variability of P. jirovecii mtDNA copy number that fluctuates
according to P. jirovecii’s physiological state, except for mtSSU that is the most stable
and the most present mitochondrial gene.
Keywords: Pneumocystis jirovecii, real-time PCR, DNA quantification, PcP, carriage, mitochondria, copy number
variation
INTRODUCTION
Pneumocystis jirovecii is an ascomycetous fungus that is specifically associated to human lung
microbiota (Cushion, 2010; Gigliotti and Wright, 2012). P. jirovecii thrives at the surface of
alveolar pneumocytes in humans but fails to grow on artificial media. However, air-liquid interface
culture system have been developed with demonstration of P. jirovecii amplification in vitro
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(Schildgen et al., 2014). These characteristics have made difficult
to study its genetic diversity, complexity and evolution in
humans. In particular, the nuclear genome of P. jirovecii has
only recently been sequenced (Cissé et al., 2012; Cushion and
Keely, 2013) and its mitochondrial genome recently described
(Ma et al., 2013). It is now well accepted that P. jirovecii
circulates within normal hosts with interhuman transmission
through air (Choukri et al., 2010; Cushion, 2010; Gigliotti
and Wright, 2012). Primary infection occurs very early in life
with almost all infants being exposed to P. jirovecii before
the age of 2 years based on serological surveys and detection
of P. jirovecii DNA in healthy children (Vargas et al., 2001;
Bishop and Kovacs, 2003). The transmission of P. jirovecii
to immunocompromised host in the absence of prophylaxis
results in progressive increase of the fungal burden in lungs
(Choukri et al., 2011). Asymptomatic carriage or colonization as
defined as detection of P. jirovecii DNA in asymptomatic patients
is common in immunocompromised population representing
about 15–20% of the patients (Alanio et al., 2011; Morris and
Norris, 2012; Mühlethaler et al., 2012). If a carrier patient
remains immunocompromised, Pneumocystis pneumonia (PCP)
can occurs within the following weeks (Mori et al., 2009). Indeed,
P. jirovecii is known to cause PCP, especially in patients with
cellular immunosuppression such as HIV-positive, solid organ
transplant and cancer/hematology patients, but also in adults and
children with other underlying conditions (Pagano et al., 2002;
Roblot et al., 2003; Catherinot et al., 2010; Wissmann et al., 2010;
Reid et al., 2011; Mori and Sugimoto, 2012; Tasaka and Tokuda,
2012). PCP symptoms have been described more severe and death
rates have been considered significantly higher in HIV-negative
in comparison to HIV-positive patients (Roux et al., 2014).
Historically, the diagnosis of PCP relied only on the
visualization of the fungal forms (trophic forms) and asci
(cysts) using classical staining (Giemsa, Gomori methenamine
silver, Toluidine Blue, Calcofluor) or direct or indirect
immunofluorescence stainings (Alanio et al., 2016b). These
methods lack sensitivity and specificity and need microscopical
expertise compared to PCR methods that have been developed
since the 1990’s (Wakefield et al., 1990). In the past 15 years,
P. jirovecii DNA amplification assays have emerged as new
diagnostic tools for PCP diagnosis especially when real-time
quantitative PCR (RT-PCR) has been used as the most reliable
method for diagnostic PCR assays (Alanio et al., 2016b).
Quantitative results are of prime interest since carrier patients
can be detected for P. jirovecii DNA as patients with PCP.
Indeed, thresholds with a gray zone have been proposed to
classify patients in terms of probability of having PCP (Flori
et al., 2004; Alanio et al., 2011; Mühlethaler et al., 2012). To
increase sensitivity, repeated targets have been selected with
the mitochondrial large ribosomal subunit (mtLSU rRNA)
as the main target used in diagnostic assay. It has been
observed by using electron microscopy that each trophic form
carried one mitochondria but the number of mitochondrial
DNA (mtDNA) copies per organism have not been clearly
investigated. According to some reports, mtDNA of P. jirovecii
may have circular configuration in contrast to closely related
species P. carini and P. murina, in which mtDNA has a linear
conformation. Despite this change in configuration, all species
share the same set of genes but in a different ordering (Ma
et al., 2013). However, the physiology of the mitochondria in
P. jirovecii is mostly unknown, which makes difficult to rely
P. jirovecii quantification only on mitochondrial genes.
The aim of this study was to analyze the quantification
of four mitochondrial genes located in different places of the
mitochondrial genome in comparison to two nuclear unique
genes in respiratory samples of patients harboring various clinical
situations.
MATERIALS AND METHODS
Ethics Statement
Saint-Louis Hospital, Paris, France, is a 650-bed tertiary
university hospital with main clinical activities in hematology
and oncology. This study was a retrospective non-interventional
study. Biological material and clinical data were obtained
only for standard diagnostic procedures following physicians’
prescriptions with no specific sampling. According to the French
Health Public Law (CSP Art L1121-1.1), such study did not
require approval of an ethics committee and is exempted from
specific informed consent application.
Patients and Clinical Samples
All P. jirovecii PCR positive clinical samples containing
more than 10 trophic form equivalents/mL, according to the
quantification method based on the qPCR assay proposed by
Alanio et al. (2011), were selected for this study. These samples
were collected from patients managed in Saint-Louis Hospital,
Paris, France, and processed and stored at −20◦C in our
laboratory. DNA extraction of the clinical samples was performed
by using a QIAamp DNA Mini kit (Qiagen, Hilden, Germany),
according to the manufacturer’s instructions as already described
(Alanio et al., 2011).
A total of 86 bronchoalveolar lavage (BAL) fluids from 84
patients were selected. Clinical (background of the patient,
the final diagnosis of the infectious episode) and biological
(immunofluorescence results, PCR quantification) parameters
were collected retrospectively from electronic patient files and
from our biological data management software, respectively. For
all analysis, only the first sample per patient was considered in the
analysis to avoid redundancy in the data.
A second cohort of 95 mtLSU rRNA PCR-negative samples
from the routine testing data was tested for the presence of mtSSU
rRNA amplification.
Real-Time Quantitative PCR Assays
Primers and probes were designed to amplify six different loci
of P. jirovecii genome using Primer3web v4.0.0 software. Four
of them (mtSSU rRNA, mtLSU rRNA, NAD1, and CYTB) were
mitochondrial genes, and two (DHPS and HSP70) were unique
nuclear genes. Sequences of primers and probes used in this
study and the size of the amplicon generated, are detailed in
Supplementary Table S1. RT-PCR assays were carried out in a
LightCycler 480 unit (Roche Diagnostics, Mannheim, Germany).
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PCR reactions were performed in 25 µl-final volume containing
0.3 µM of each pair of primers and 0.1 µM of probe for
each target tested in the assay. For mtLSU, DHPS, NAD1, and
mtSSU quantification assays, 2x LightCycler 480 Probes Master
(Roche Diagnostics, Mannheim, Germany) was used, whereas
2x TaqMan Universal PCR Master Mix (Applied Biosystems,
Foster City, CA, USA) was added for CYTB and HSP70
quantification analysis. Finally, 5 µl of DNA extracted from
clinical samples were added in duplicate to each quantification
assay. PCR conditions were as follows: an initial step of 10 min
at 95◦C, following by 45 cycles at 95◦C for 15 s and 60◦C for
30 s with an ending cooling phase of 30 s at 40◦C. Results
were considered positive when the fluorescent signal above the
baseline was detected, as determined by second-derivate analysis
and were expressed in terms of the quantification cycle (Cq). Each
experiment included a positive control consisted in a dilution of
DNA extracted from a controlled clinical sample positive for PCP
at high fungal load as well as negative controls.
Standardization and Data Analysis
A standard curve for each genomic target allowing PCR efficiency
calculation was obtained based on the result of two PCR
repetitions with five 10-fold serial dilutions of a controlled DNA
extracted from a clinical sample positive for PCP at high fungal
load and previously quantified by RT-PCR (Alanio et al., 2011).
Regression lines were constructed automatically by plotting
the logarithm of the initial template concentration versus the
corresponding Cq value by using Analysis package included in
LightCycler 480 software v. 1.5 (Roche Diagnostics, Mannheim,
Germany). For the calculation of the copy number, the minimal
Cq value obtained was selected from the duplicates values. The
Cq ratio between each mitochondrial gene and the geometric
mean of the two monocopy nuclear genes was calculated as
described by Pfaﬄ (2001) and Vandesompele et al. (2002). The
geometric mean of two monocopy nuclear genes was considered
as the best value representing the nuclear genome and called
“nuclear genes” along the manuscript.
Finally, a specificity test was performed by testing a
panel of different fungal DNAs at 0.01 ng/µL for each
target analyzed in this work. DNAs tested belonged to
fungal species present, normally, in the human respiratory
tract: Aspergillus fumigatus Af293, A. niger CNRMA15.743,
Rhizopus microsporus CNRMA14.351, Mucor circinelloides
CNRMA16.241, Candida albicans CNRMA16.291, C. glabrata
CNRMA16.324, Cryptococcus neoformans CNRMA16.024,
Trichosporon asahii CBS2479, Malassezia furfur CNRMA15.762,
identified at the French National Reference Center for Invasive
Mycoses and Antifungals.
Statistical and Graph Analysis
Physical mapping of the P. jirovecii mitochondrial DNA was
generated in Geneious software v.8.1.5. based on the JX499143
sequence provided by Ma et al. (2013).
Box-and-whisker plots with minimum-maximum were used
for data representation. For comparisons, we performed unpaired
t-test and ANOVA analysis for normally distributed data and
Mann–Whitney and Kruskal–Wallis tests for data that were not
normally distributed, and χ2 test and Fisher’s exact test for
contingency tables analyses. Median and interquartile ranges
are described in the text. P-values of <0.05 were considered
significant and the p-value was indicated by asterisks as follows:
∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, ∗∗∗∗p ≤ 0.0001. Both
graphs and statistical analysis were performed by using Prism
6.0 (GraphPad Software Inc., La Jolla, CA, USA). Hierarchical
clustering analysis (HCA) of samples was performed by using
TIGR Multiexperiment Viewer (MeV) software v4.6.1 (Saeed
et al., 2003).
RESULTS
Six Real-Time Quantitative PCR Assay
for Determining Mitochondrial DNA Copy
Number Variation (CNV)
Copy number of mitochondrial genes (mtLSU, mtSSU, NAD1,
and CYTB, Supplementary Figure S1) was calculated using
qPCR. All the six qPCR assays were optimized (Supplementary
Figures S2–S4). A positive control DNA stored at −20◦C as
12 µL aliquots was run to validate each run. PCR efficiencies
calculated based on 10-fold serial dilutions of the positive control
DNA were as follows: mtLSU rRNA, E = 1.938; CYTB, E = 1.97;
NAD1, E = 1.968; mtSSU rRNA, E = 1.931; DHPS, E = 1.932
and HSP70, E = 1.95 (Supplementary Figure S5). Minimum
Cq results of the six genes were used to calculate the ratio
TABLE 1 | Main clinical and biological characteristics of the patients and
samples (n = 84) included in the study.
Number of samples
(n = 84)
mtLSU Cq
(mean ± SD)
CLINICAL CHARACTERISTICS
Underlying disease
HIV 20 /
Kidney SOT 8 /
Hematology disease 35 /
Others 18 /
na 3 /
Final clinical diagnosis
PCP 44 28.42 ± 4.24
PCC 34 33.75 ± 2.18
na 6 30.87 ± 3.48
BIOLOGICAL CHARACTERISTICS
Fungal load
High (Cq < 30) 29 25.60 ± 2.69
Medium (30 < Cq > 34) 31 32.29 ± 1.20
Low (Cq > 34) 24 35.00 ± 0.72
IF assay
IF+ 24 26.33 ± 3.76
IF− 54 33.01 ± 2.56
na 6 28.13 ± 3.94
HIV, human immunodeficiency virus; SOT, solid organ transplant; PCP,
Pneumocystis pneumonia; PCC, Pneumocystis carriage; IF, immunofluorescence;
BAL, bronchoalveolar lavage fluids; na, non-available data.
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FIGURE 1 | Pneumocystis jirovecii fungal load varies according to the clinical background of the patients. The distribution of P. jirovecii quantification in
bronchoalveolar lavage fluid (BAL) of patients with different clinical background (HIV positive patients, solid organ transplant patients or other background) is shown
for high or medium/low fungal loads (A,B) or for immunofluorescence (IF)-positive or -negative BAL (C,D) as quantified using mtLSU rRNA gene (A,C) or nuclear
genes (B,D). P-values indicating the significance of the differences are indicated in the top of the figure for each category.
between each mitochondrial gene and the geometric mean of the
two nuclear genes. The mean Cq value of the positive control
DNA included in each PCR assay was 29.18 ± 0.3 for mtSSU
rRNA, 30.30 ± 0.28 for mtLSU rRNA, 29.16 ± 0.16 for NAD1,
30.87 ± 0.36 for CYTB, 34.69 ± 0.43 for DHPS and 35.98 ± 0.58
for HSP70.
In order to evaluate the specificity of the assay, DNAs
belonging to nine different fungal species were tested for all genes
studied in this work. No cross-reactivity to any of the tested fungi
was detected.
The P. jirovecii Fungal Load Does Not
Reflect the Results of
Immunofluorescence and the Final
Clinical Diagnosis
According to clinical sample selection criteria explained in
section “Materials and Methods” (see Patients and clinical
samples), 84 BAL fluids were finally included in the study. The
median age of patients was 61 years and the male:female ratio
was 1.6:1. Clinical and biological parameters are summarized in
Table 1.
In BAL samples with high fungal load, the load was
significantly different regarding the background of the patient
(HIV, SOT, hematology, others), as determined from mtLSU
rRNA (p = 0.044) and from nuclear genes (p = 0.014)
quantification with significant differences between HIV and
hematology patients (mtLSU Cq, p = 0.0015; nuclear genes
Cq, p = 0.0007) and HIV and other backgrounds (nuclear
genes, p = 0.011) (Figures 1A,B), but not with NAD1 or
CYTB (Supplementary Figures S6A,B). In samples with medium
or low fungal load, no differences were observed between
the different clinical backgrounds (p > 0.05). In contrast, no
significant difference (p > 0.05) was observed between the
different clinical backgrounds in immunofluorescence positive
or negative BAL samples for mtLSU rRNA (Figure 1C) or
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FIGURE 2 | Immunofluorescence assay and final clinical diagnosis does not reflect P. jirovecii fungal load in BAL samples. Quantification of the six
genes included in the study regarding immunofluorescence results of clinical samples (A). Large overlaps between the low IF+ sample and the higher IF− samples
are highlighted with color boxes. The number and percentages of samples included in those overlaps are detailed in the top of the figure for each gene. mtLSU rRNA
gene quantification in HIV+ and HIV− patients for immunofluorescence-positive, high fungal load and final clinical diagnosis (B). mtLSU rRNA gene quantification
regarding final clinical diagnosis, immunofluorescence results and fungal load in HIV positive (C) patients and HIV negative (D) patients. ∗ indicates that this situation
was not present in our dataset.
nuclear genes (Figure 1D). The same feature was observed for
the final diagnosis classification (PCP vs. PCC) (Supplementary
Figures S6C,D)
A large overlap of BAL fungal load is observed regarding the
results of immunofluorescence in all six genes with 34–54% of the
samples included between the last IF+ and the first IF− sample,
as highlighted in color (Figure 2A). In addition, the BAL fungal
load as determined by mtLSU rRNA Cq was plotted regarding
the result of immunofluorescence and the final diagnosis retained
by the clinicians (Figure 2B). Large overlaps between PCP and
PCC patients are observed in each category either in HIV+
patients (Figure 2C) or in HIV- patients (Figure 2D) preventing
determination of absolute thresholds.
Mitochondrial Genes Harbor Different
Copy Numbers, Which Vary the
According to the Fungal Load
The median number of copies of the four mitochondrial genes
varies compared to nuclear genome with mtSSU, mtLSU, NAD1,
and CYTB harboring a median copy number of 37 [interquartile
range, 23–64], 15 [8–25], 23 [12–39], 6 [2–11], compared to the
geometric mean of DHFR, HSP70 (nuclear genome), respectively
(Figure 3A).
Hierarchical clustering analysis of 74 of the 84 BALs based
on the variation of copy number of mitochondrial genes from
the median value allowed us to define five major clusters (≥6
samples per cluster): cluster 1 (n = 8), cluster 3 (n = 11),
cluster 4 (n = 6), cluster 6 (n = 23) and cluster 7 (n = 23)
(Figure 3B). Of note, mitochondrial CNV was not calculable for
the 10 BALs for which no amplification of the nuclear genes
(DHPS and HSP70) was observed. CNV of all mitochondrial
genes were statistically different among all clusters described.
However, the difference between the number of copies of the four
genes is less important in the 23 samples from cluster 7 (C7)
(Figure 3C).
These five clusters were significantly associated with the
fungal load (high vs. medium/low, p = 0.029) but not with
immunofluorescence (IF+ vs. IF−, 0.11) or clinical status
(PCP vs. PCC, p = 0.137) (Table 2). In details, C1 was
significantly associated with medium/low fungal load (0%
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FIGURE 3 | Copy number variation of four mitochondrial genes. Copy number variation (CNV) of P. jirovecii mitochondrial genes varies from gene to gene with
a median of six copies for CYTB, 23 for NAD1, 15 for mtLSU, and 37 for mtSSU compared to the mean of two nuclear genes (DHPS and HSP70) (A). Median copy
number is indicated in the top of the figure for each target. Heat map of the copy number of the four mitochondrial genes of the 74 BALs as the result of hierarchical
clustering analysis (HCA) (B). Five major clusters containing ≥6 samples were defined as indicated between bars (B) with the detailed quantification of each gene
within each cluster (C). P-values indicating the significance of the differences between each gene in a given cluster and indicated in the top of the figure for each
category.
vs. 18.2%, p = 0.020). Significant differences in the CNV
between high and medium/low fungal loads were observed
for mtLSU (p = 0.037), NAD1 (p = 0.0061), and CYTB
(p < 0.0001) (Figure 4A). The ratio of these genes between
high and medium/low fungal loads were significantly different
(p < 0.0001), except for the mtLSU/NAD1 ratio (p = 0.187)
(Figure 4B). The CNV of NAD1 and CYTB and all the
ratios were still significantly different when three categories
of fungal load were taken into account (high vs. medium
vs. low, Supplementary Figures S7A,B). Differences for the
CYTB gene (Supplementary Figures S8A,C) and all ratios for
regarding IF results and final clinical diagnosis were significant
(p < 0.05) except for the mtLSU/NAD1 ratio regarding IF results
(Supplementary Figures S8B,D).
mtSSU rRNA Target Is Detected in
mtLSU rRNA Negative Samples
Since mtSSU rRNA was demonstrated to be present with
a higher number of copies compared to mtLSU rRNA,
with a 2.5 times more quantification compared to mtLSU
rRNA (37/15 copies; Figure 3A), we tested a second cohort
of negative-mtLSU rRNA PCR samples for mtSSU rRNA
amplification. Three samples (two patients) out of 95 were
positive for mtSSU rRNA amplification. Two of them were
a bronchial aspirate (Cq: 34.69) and a BAL fluid (Cq:
33.50) both for the same patient, whereas the remaining
one was a induced-sputum (Cq: 33.13) for a patient with
a BAL positive for mtLSU rRNA amplification but with less
than 10 trophic form equivalents/mL (4.5 TfEq/mL). These
patients were given anti-P. jirovecii prophylaxis after the
clinical episode and did not develop PCP within the next
2 years.
DISCUSSION
PCR assays are now considered as the most useful tool
for pneumocystosis diagnosis, especially in HIV-negative
immunocompromised patients, with an excellent negative
predictive value and a high level of suspicion when PCR is
positive (Alanio et al., 2016b). The most commonly used PCR
assay is based on the amplification of mitochondrial large subunit
ribosomal gene (mtLSU rRNA). This target has been proposed
and used for 25 years (Wakefield et al., 1990; Meliani et al.,
2003; Aderaye et al., 2008; Alanio et al., 2011; Hauser et al.,
2011; Botterel et al., 2012). Multicopy genes have been shown
to lead to increased detection of P. jirovecii. Indeed, mtLSU
(Montesinos et al., 2015) and MSG (Linssen et al., 2006) PCR
Frontiers in Microbiology | www.frontiersin.org 6 September 2016 | Volume 7 | Article 1413
fmicb-07-01413 September 8, 2016 Time: 13:13 # 7
Valero et al. CNV of Pj Mitochondrial DNA Genes
TABLE 2 | Distribution of the samples according to the hierarchical
clustering algorithm (HCA) clusters and the fungal load,
immunofluorescence or final clinical diagnosis.
HCA clusters
C1 C3 C4 C6 C7 p∗
High fungal load
(%) n = 27
0 (0) 2 (7.4) 4 (14.8) 9 (33.3) 12 (44.4) 0.029
Medium/low fungal
load (%) n = 44
8 (18.2) 9 (20.4) 2 (4.5) 14 (31.8) 11 (25)
IF+ (%) n = 23 1 (4.3) 2 (8.7) 2 (8.7) 7 (30.4) 11 (47.8) 0.111
IF− (%) n = 42 7 (16.6) 9 (21.4) 4 (9.5) 14 (33.3) 8 (19)
PCP (%) n = 41 2 (4.9) 5 (12.2) 4 (9.8) 14 (34.14) 16 (39) 0.137
PCC (%) n = 26 6 (23.1) 5 (19.23) 1 (3.8) 8 (30.8) 6 (23.1)
∗Chi-2 test.
assays gave increased sensitivity compared to unicopy genes
(DHPS or β-tubulin). However, strict comparison of mtLSU and
unique gene PCR assays had not been performed until now. In
our study, we designed and optimized six PCR assays including
four mitochondrial genes assays [mtLSU (Alanio et al., 2011),
mtSSU, NAD1, and CYTB] and two unique nuclear gene assays
(DHPS, HSP70), with the initial idea to evaluate the number
of mitochondrial DNA copies compared to nuclear unique
genes. Primer concentration, buffer from different suppliers,
and PCR cycles protocols were optimized (see Supplementary
Figures S2–S5) and efficiencies calculated to allow accurate
copy number calculations following accurate calculations (Pfaﬄ,
2001). We then screened a collection of 84 BALs selected to
harbor more than 10 EqTr/ml using mtLSU PCR assay to
increase the chance to get amplification for nuclear unique
genes.
The result of the immunofluorescence (IF) assay (positive
vs. negative), the PCR fungal load (high vs. medium/low) and
the final clinical diagnosis of the episode based on electronic
file of the patient’s episode [pneumocystosis (PCP), vs. carriage
(PCC)] were first analyzed regarding that of our six PCR assays.
As observed before in literature (Mühlethaler et al., 2012), we
observed a large overlap in terms of fungal load between IF+
and IF− samples suggesting that the result the IF assay does
not reflect perfectly the fungal load in respiratory samples. This
can be explained by intrinsic technical issues of IF assay (limited
amount of material spotted on slices, variability of the quality
of the samples, restriction at ≥3 elements for positive results
according to manufacturer’s recommendations, non-specificity of
the shape of the acsi compared to yeasts). Another explanation
is given by the potential differences in the trophic forms/asci
ratio known as about 1:10 in HIV positive patients with PCP
and also known to vary upon drug exposure (Tamburrini et al.,
1996). If the generation of acsi is impaired for some reason, PCR
assays will detect more DNA from trophic forms than from the
acsi that would have been missed by the IF assay. This could
explain why in our BAL samples about 34–54% of the samples
were included in the overlap between the first IF− and the last
IF+ samples.
We also found that the final clinical diagnosis as retained
by the clinician was not linked to the fungal load. Indeed,
we found patients harboring the same fungal load classified as
PCP or PCC. No significant difference was observed between
fungal loads of PCP patients between HIV+ and HIV− patients
although differences were significant when fungal load or IF
was considered, which is consistent with literature (Alanio et al.,
2011; Botterel et al., 2012; Louis et al., 2015). It is interesting
to consider that the clinical decision is not based only on
the result of biological tests but include also a broader view
including pretest probability, radiological findings, background
of the patient, initial evolution, occurrence of co-pathogens,
experience of the clinician (Islam et al., 2015). Indeed, four
out of five HIV+ patients with CD4 counts <200/mm3 were
classified as PCP with IF− and a medium/low fungal load.
This clinical decision is coherent with the fact that P. jirovecii
found in an immunocompromised host even with a medium
or low fungal load should be considered carefully in terms of
treatment, as recommended in non-HIV immunocompromised
patients (Alanio et al., 2016b). Given these observations, it
appears that the fungal load would be the most objective criteria
for further analysis that prevent any bias due to technical or
clinical interpretation.
Using our assays, we observed intriguingly that the number
of copies for four mitochondrial genes were different in all the
84 samples, although for the 23 samples from cluster 7, the
difference was significant but less noticeable (Figures 3B,C).
Mitochondrial DNA (mtDNA) is supposed to be circular in
P. jirovecii as opposed to P. carinii or P. murina for which a
linear structure have been proposed (Ma et al., 2013) and so,
each gene is supposed to be present once per mtDNA copies and
harboring the same number of copies compared to nuclear genes.
Interestingly, mtLSU rRNA (median of 15 copies per nuclear
genome) and CYTB (median of 6 copies per nuclear genome)
assays gave less copy number than NAD1 (median of 23 copies
per nuclear genome) or mtSSU rRNA (median of 37 copies per
nuclear genome).
Our hypothesis is that in P. jirovecii, several mtDNA
‘species’ coexists with some of them amplified more than others
(Figure 5). This is supported by the fact that the physical mapping
of the mitochondrial genes [Supplementary Figure S1, (Ma
et al., 2013)] showed that NAD1 and mtSSU rRNA are closer
together than with the other genes. Indeed, one can imagine that
a mtDNA subspecies including NAD1 and mtSSU rRNA could be
overrepresented compared to other subspecies and compared to
the whole mtDNA. The technique used to describe the sequence
of P. jirovecii was Sanger sequencing from conserved mtDNA
regions of P. murina and P. carinii after cloning and endpoint
PCR (Ma et al., 2013). Indeed, this method does not accurately
detect subspecies of mtDNA but is accurate to determine the
synteny of mitochondrial genes when at least one entire copy of
the mtDNA is present in the sample. This observation needs to
be analyzed in parallel with another observation we did recently
using other samples on mitochondrial heteroplasmy and mtDNA
recombination in P. jirovecii (Alanio et al., 2016a). Unfortunately,
we were not able to validate this hypothesis using endpoint PCR.
This can be explained by the fact that large PCR amplicons
(>2 kbp) are difficult to obtain in complex DNA extracts as BAL
fluids or by the fact that these subspecies are linear preventing
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FIGURE 4 | Copy number variation of mitochondrial genes varies according to the fungal load. CNV is significantly different in samples with high and
medium/low fungal loads for mtLSU, CYTB and NAD1 but not for mtSSU (A). Each ratio of the DNA of the four mitochondrial genes is significantly different in
samples with high and medium/low fungal loads except mtLSU/NAD1 (B). P-values indicating the significance of the differences are indicated in the top of the figure
for each category.
FIGURE 5 | Model for the dynamics of P. jirovecii mtDNA. High number
of mtDNA subspecies is found together with the whole mtDNA species with
variation of different subspecies according to the physiology of P. jirovecii
(fungal load). A subspecies containing mtSSU and NAD1 is present with a
higher number copy compared to other mtDNA subspecies.
amplification of the remaining DNA part that could have been
amplified if it is circular.
Interestingly, we found that the number of copies of
the different genes vary regarding the fungal load with
discrimination between high, medium and low fungal loads.
This supports the hypothesis of differential amplification of
some subspecies of mtDNA regarding the metabolism state
of P. jirovecii. A high fungal load would be related to
highly proliferating organisms whereas medium/low fungal
loads to a less proliferating or a more quiescent state. One
can imagine that the physiology of mitochondria would be
different in these two situations as already suggested in
Cryptococcus neoformans (Alanio et al., 2015; Rocheteau et al.,
2015), with the differential amplification of some subspecies
in these different biological situations, as observed in our
study.
In humans, deletion of mitochondrial genes, described as
mtDNA depletion syndromes, leads to severe diseases with poor
prognosis by impaired energy production affecting different
organs like brain, muscles, liver, and digestive tract (El-Hattab
and Scaglia, 2013). However, for P. jirovecii, alteration of
mitochondrial metabolism should not lead to such extremity,
due to its adaptation to host parasitism at the surface of the
human alveoli. P. jirovecii has been shown to uptake from host
several factors it is unable to synthesize and the proteins involved
in mitochondrial metabolisms should be one of these factors
(Ma et al., 2016). Indeed, P. jirovecii has lost synthetic pathways
such as coenzyme A, thiamine, Glyoxylate, gluconeogenesis, and
fermentation, pathways in which mitochondria plays a role, with
uptake from lung as a mean to obtain these metabolites (Ma et al.,
2016).
We also found that mtSSU rRNA is constantly present
with a higher number of copies compared to mtLSU rRNA
with a median ratio of 2.5 copies. This finding suggests that
mtSSU rRNA could be present twice in the P. jirovecii mtDNA.
In addition, mtSSU rRNA was demonstrated to be a more
sensitive target to detect P. jirovecii in respiratory samples
since some mtLSU negative/mtSSU positive samples were
found in our collection. This is of prime importance since
immunocompromised patients with a positive P. jirovecii PCR
in respiratory samples would benefit from a prophylactic
treatment since detection of P. jirovecii at low fungal
load could be the first step before the development of
pneumocystosis (Mori et al., 2009). Interestingly, mtSSU
rRNA is the most stable mitochondrial marker regarding
fungal load, immunofluorescence results or final clinical
diagnosis. All these data suggest that mtSSU PCR assay
is the best PCR assay to detect P. jirovecii in humans.
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To conclude, further studies on P. jirovecii mitochondria are
highly needed to validate our hypothesis suggesting plasticity of
P. jirovecii mitochondrial genome (increased or decreased copy
number) and to validate hypotheses from our previous work
suggesting heteroplasmy and mtDNA recombination (Alanio
et al., 2016a), but its unculturable feature prevents the easy
implementation of such studies.
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FIGURE S1 | Genetic map of Pneumocystis jirovecii mtDNA based on
JX499143 sequence is shown in linear configuration. mtSSU rRNA, mtLSU
rRNA, NAD1, and CYTB genes are shown emphasized within the figure.
FIGURE S2 | Optimization of qPCR assays I. mtLSU rRNA gene (top of the
figure) was tested with Roche mastermix (LightCycler 480 Probes Master, Roche
Diagnostics, Mannheim, Germany) and 0.3 µM of each primer and 0.1 µM of
probe (top left panel), 0.5 µM of each primer and 0.25 µM of probe (top right
panel), 0.6 µM of each primer and 0.3 µM of probe (lower left panel) and 0.3 µM
of each primer and 0.1 µM of probe again but with Applied mastermix (TaqMan
Universal PCR Master Mix, Applied Biosystems, Carlsbad, CA, USA) (lower right
panel). mtSSU rRNA gene (beneath of the figure) was tested with 0.3 µM of each
primer and 0.1 µM of probe with Roche (left panel) and Applied (right panel)
matermixes. Cq values obtained for each dilution of positive control DNA as well
as efficiency calculated with those data are represented in a table next to the
panels. Optimal PCR conditions are highlighted in color.
FIGURE S3 | Optimization of qPCR assays II. CYTB gene (top of the figure)
was optimized by testing Roche mastermix with 0.3 µM of each primer and
0.1 µM of probe (top left panel), 0.5 µM of each primer and 0.25 µM of probe (top
right panel), 0.6 µM of each primer and 0.3 µM of probe (lower left panel) and
0.3 µM of each primer and 0.1 µM of probe again but with Applied mastermix
(lower right panel). NAD1 gene (beneath of the figure) was tested with 0.3 µM of
each primer and 0.1 µM of probe with Roche (left panel) and Applied (right panel)
matermixes. Cq values obtained for each dilution of positive control DNA as well
as efficiency calculated with those data are represented in a table next to the
panels. Optimal PCR conditions are highlighted in color.
FIGURE S4 | Optimization of qPCR assays III. DHPS gene (top of the figure)
was optimized by testing Roche mastermix with 0.3 µM of each primer and
0.1 µM of probe (top left panel), 0.5 µM of each primer and 0.25 µM of probe (top
right panel), 0.6 µM of each primer and 0.3 µM of probe (lower left panel) and
0.3 µM of each primer and 0.1 µM of probe again but with Applied mastermix
(lower right panel). HSP70 gene (beneath of the figure) was tested with 0.3 µM of
each primer and 0.1 µM of probe with Roche (left panel) and Applied (right panel)
matermixes. Cq values obtained for each dilution of positive control DNA as well
as efficiency calculated with those data are represented in a table next to the
panels. Optimal PCR conditions are highlighted in color.
FIGURE S5 | Optimization of qPCR assays IV. Optimal PCR conditions are
shown at once.
FIGURE S6 | Pneumocystis jirovecii quantification regarding clinical
background of patients. NAD1 quantification in high fungal load samples (left)
and medium/low fungal load (right) (A). CYTB quantification in high fungal load
samples (left) and medium/low fungal load (right) (B). mtLSU rRNA quantification
in PCP samples (left) and PCC (right) (C). Nuclear genes quantification PCP
samples (left) and PCC (right) (D).
FIGURE S7 | Copy number variation of mitochondrial genes varies
according to the fungal load. CNV is significantly different in samples with high,
medium and low fungal loads for CYTB and NAD1 but not for mtLSU or mtSSU
(A). All ratio of the DNA of the four mitochondrial gene is significantly different in
samples with high medium or low fungal loads (B). P-values indicating the
significance of the differences are indicated in the top of the figure for each
category.
FIGURE S8 | Copy number variation of mitochondrial genes do not vary
according to immunofluorescence results and final clinical diagnosis. CNV
of mitochondrial genes in IF+ and IF− samples (A). CNV in ratios between these
mitochondrial genes in IF+ and IF− samples (B). CNV of mitochondrial genes in
PCP and PCC samples (C) CNV in ratios between these mitochondrial genes in
PCP and PCC samples (D). P-values indicating the significance of the differences
are indicated in the top of the figure for each category.
Table S1 | Sequences and targets of primers and probes used in P. jirovecii
quantification assays and their corresponding amplicon sizes.
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